Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 3 days ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
Glucagon-Containing Dual and Triple Agonists For Obesity and MASH
Author(s): Scott Harris Added: 10 months ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
EASD 24: Effectiveness of Empagliflozin and GLP1s
Author(s): Phyo Htoo Added: 8 months ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 1 month ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Luis Castilla-Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 3 months ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Heart Failure

Prevention & Chronic Conditions
Updates on Chronic Coronary Syndrome
Author(s): Filippo Gurgoglione , Giampaolo Niccoli Added: 6 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 11 months ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
EASD 23: Efinopegdutide in NAFLD & T2D patients
Author(s): Samuel S Engel Added: 1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
NF-kB in Cardiovascular Disease
Author(s): Akira Matsumori Added: 1 year ago

Vascular Disease and Surgery

Imaging & Diagnostics